Informing vaccine design and development
Our TCR-antigen discovery capabilities may inform the design and development of next-generation vaccines. Adaptive has validated hundreds of immunogenic antigens that can be selected to design differentiated vaccines. Our platform is also used to detect and track vaccine-induced antigen-specific T cell responses that correlate with efficacy and safety.
Our antigen specificity approach may be used to identify and inform the selection of the most immunogenic antigens to use in the development of either an “off-the-shelf” or a personalized vaccine.
*MIRA is for research use only. Not for use in diagnostic procedures.